Loading…
Codexis, Inc. is projected to rise to $3.08 by 2027, a +27% move from its current price of $2.43. CDXS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.35 | $2.43 | $2.52 | +0.07% |
| Jul 14 | $2.32 | $2.43 | $2.56 | +0.13% |
| Jul 15 | $2.29 | $2.43 | $2.59 | +0.20% |
| Jul 16 | $2.27 | $2.44 | $2.61 | +0.27% |
| Jul 17 | $2.26 | $2.44 | $2.64 | +0.33% |
| Jul 18 | $2.24 | $2.44 | $2.66 | +0.40% |
| Jul 19 | $2.23 | $2.44 | $2.68 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.23 | $2.44 | $2.68 | +0.47% |
| Week 2 | $2.15 | $2.45 | $2.79 | +0.93% |
| Week 3 | $2.10 | $2.46 | $2.89 | +1.40% |
| Week 4 | $2.06 | $2.48 | $2.98 | +1.88% |
| Week 5 | $2.02 | $2.49 | $3.06 | +2.35% |
| Week 6 | $1.99 | $2.50 | $3.13 | +2.83% |
| Week 7 | $1.97 | $2.51 | $3.20 | +3.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes. It also develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
The company has a license agreement with Aldevron LLC and Pfizer Inc. Codexis was incorporated in 2002 and is headquartered in Redwood City, California. It sits in the Healthcare sector.
Codexis, Inc. (CDXS) is currently priced at $2.43 and has a market capitalization of $220.88M, ranking 3733 by market cap. This positions the stock as a smaller-cap healthcare name with a defined price point for investors to consider against its sector peers.
The 30-day price range spans $1.93 to $3.06, providing context for near-term volatility around the current level.
A major floor 59.7% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 15.2% above — a clean break opens room to run.
A major ceiling 25.2% above — clearing it would confirm fresh momentum.
Key CDXS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CDXS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.57 | Sell | $2.51 | Sell |
| MA 10 | $2.47 | Sell | $2.49 | Sell |
| MA 20 | $2.44 | Sell | $2.48 | Sell |
| MA 50 | $2.55 | Sell | $2.43 | Sell |
| MA 100 | $2.14 | Buy | $2.28 | Buy |
| MA 200 | $2.02 | Buy | $2.24 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.69 | Neutral |
| Stoch RSI (14) | 44.55 | Neutral |
| CCI (20) | -7.02 | Neutral |
| Williams %R (14) | -56.10 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 1.67 | Buy |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 43.90 | Neutral |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 55.07 | Neutral |
| Momentum (10) | 0.18 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 2.59 | Sell |
| ADX (14) | 11.05 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day sentiment is BULLISH, with RSI14 at 50. The trend is framed by the SMA50 at $2.55 and the SMA200 at $2.02, offering a short-term view of how prices are tracking relative to.key moving averages. Support is at $2.25 and resistance at $2.80, suggesting a defined trading range in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.98 | $2.43 | $3.49 | 0% | Neutral | |
| $2.39 | $3.08 | $4.24 | +27% | Bullish | |
| $2.95 | $3.94 | $5.68 | +62% | Bullish | |
| $3.13 | $4.32 | $6.44 | +78% | Bullish | |
| $3.40 | $4.82 | $7.39 | +98% | Bullish | |
| $5.01 | $7.27 | $11.46 | +199% | Bullish | |
| $5.86 | $8.71 | $14.04 | +258% | Bullish | |
| $6.35 | $9.65 | $15.88 | +297% | Bullish | |
| $7.02 | $10.90 | $18.28 | +349% | Bullish | |
| $6.69 | $10.60 | $18.09 | +336% | Bullish | |
| $12.94 | $22.53 | $41.35 | +827% | Bullish | |
| $23.58 | $48.56 | $98.98 | +19.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.98 | $2.43 | $3.05 | +0.00% |
| August 2026 | $2.18 | $2.59 | $3.17 | +6.51% |
| September 2026 | $2.15 | $2.58 | $3.21 | -0.25% |
| October 2026 | $2.22 | $2.69 | $3.38 | +4.07% |
| November 2026 | $2.28 | $2.77 | $3.52 | +3.09% |
| December 2026 | $2.23 | $2.73 | $3.49 | -1.60% |
Click any year to see its month-by-month CDXS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Codexis, Inc.'s 2026 outlook centres on $2.43, within a $0.98 to $3.49 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CDXS could reach as high as $4.24, with a base case around $3.08 and support toward $2.39 — roughly +27% from $2.43. Momentum favours further upside here.
Expect CDXS to range from $2.95 to $5.68 through 2028. The $3.94 average target implies a +62% move from current prices. That is up +28% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CDXS price prediction for 2029 points to an average of $4.32 (low $3.13, high $6.44) — a potential gain of +78% on today's $2.43. Momentum favours further upside here.
In 2030, CDXS is projected to trade between $3.40 and $7.39, averaging $4.82 — a potential gain of +98% from today's $2.43. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Codexis, Inc.'s 2031 outlook centres on $7.27, within a $5.01 to $11.46 range. That is up +51% on the projected 2030 average. That marks a +199% change versus current levels. Momentum favours further upside here.
By 2032, CDXS could reach as high as $14.04, with a base case around $8.71 and support toward $5.86 — roughly +258% from $2.43. Buyers look set to stay in control over this stretch.
Expect CDXS to range from $6.35 to $15.88 through 2033. The $9.65 average target implies a +297% move from current prices. That is up +11% on the projected 2032 average. Momentum favours further upside here.
The CDXS price prediction for 2034 points to an average of $10.90 (low $7.02, high $18.28) — a potential gain of +349% on today's $2.43. Buyers look set to stay in control over this stretch.
In 2035, CDXS is projected to trade between $6.69 and $18.09, averaging $10.60 — a potential gain of +336% from today's $2.43. That is -3% versus the projected 2034 average. Momentum favours further upside here.
Codexis, Inc.'s 2040 outlook centres on $22.53, within a $12.94 to $41.35 range. That is up +112% on the projected 2035 average. That marks a +827% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CDXS could reach as high as $98.98, with a base case around $48.56 and support toward $23.58 — roughly +19.0x from $2.43. Momentum favours further upside here.
Investing $1,000 in CDXS today (≈ 411.522634 CDXS) could be worth
$19,982.77
+$18,982.77 (+1898%) by 2050 · US Dollar
Based on the average projected CDXS price of $48.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CDXSwould be worth at today's price.
$1,000 invested in CDXS on Jul 10, 2025 (≈ 321.543419 CDXS) would be worth
$781.35
-$218.65 (-21.9%) today · 0.78× · US Dollar
Based on a CDXS entry price of $3.11 vs. today's $2.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.47 | $983.81 | -1.6% |
| 1 month ago | $2.35 | $1,034.04 | +3.4% |
| 3 months ago | $2.24 | $1,084.82 | +8.5% |
| 6 months ago | $1.68 | $1,446.43 | +44.6% |
| 1 year ago | $3.11 | $781.35 | -21.9% |
| All time (5.0y) ago | $21.11 | $115.11 | -88.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CDXS forecast.
Our base-case forecast reaches $4.90 around 2031.
Implied market cap at $4.90: $445.39M
The multi-year forecast shows a path of upside with year-by-year averages. In 2026 the avg is $2.43 with a min of $0.98 and a max of $3.49, ROI 0 and sentiment NEUTRAL. By 2030, the avg rises to $4.82 with a min of $3.40 and a max of $7.41, ROI 98.5 and sentiment BULLISH, and by 2035 the avg is $10.60 with a min of $6.69 and a max of $18.08, ROI 336.1.
The trajectory continues to 2040 with an avg of $22.54 (min $12.94, max $41.37; ROI 827.4) and 2050 with an avg of $48.54 (min $23.57, max $98.95; ROI 1897.6) all with bullish sentiment. These figures illustrate substantial potential upside over the long term, but they are estimates and not guarantees.
Tap a question to reveal the answer.
2030 avg $4.82; min $3.40; max $7.41; ROI 98.5%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages (e.g., 2027 avg $3.09; 2028 avg $3.95; 2029 avg $4.32; 2030 avg $4.82). In 2026 the avg is $2.43 with ROI 0, indicating near-term neutrality but upside potential later in the forecast.
The forecast shows higher-price years; for example, 2033 has avg $9.66 and max $15.89 with ROI 297.4, indicating the potential to exceed $10 within the forecast horizon.
The current price is $2.43.
2040 min $12.94, avg $22.54, max $41.37, ROI 827.4, sentiment BULLISH.
Codexis, Inc. Community Discussion
0Share your Codexis, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.